Anika Therapeutics, Inc.: accounts_receivable
| Value | {"amount": 35961000, "concept": "us-gaap:AccountsReceivableNetCurrent", "currency": "USD"} |
|---|---|
| Period | (as of 2023-12-31) |
| Status | superseded |
| Entity | Anika Therapeutics, Inc. |
Provenance
Source: SEC EDGAR CompanyFacts (US-PD-17USC105)
Reference:
Retrieved: 2026-08-19T09:02:51.542883+02:00
Raw response sha256:
Also addressable by official identifiers:
Cite as: FACTANKER, https://factanker.com/fact/5dd53f87-d3bc-4ee4-8007-3ab600493063
Source: SEC EDGAR CompanyFacts (US-PD-17USC105)
Reference:
0001171843-24-001380Retrieved: 2026-08-19T09:02:51.542883+02:00
Raw response sha256:
f7bde1a401b286c74a2fd824ee1df541…Also addressable by official identifiers:
https://factanker.com/fact/sec/cik-0000898437/accounts-receivable/2023-12-31 (CIK, metric, reporting date)Cite as: FACTANKER, https://factanker.com/fact/5dd53f87-d3bc-4ee4-8007-3ab600493063
History
- no predecessors — first report